These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15520506)

  • 1. Doxepin inhibits CYP2D6 activity in vivo.
    Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
    Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of clomipramine on CYP2D6 activity].
    Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P
    Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.
    Kirchheiner J; Henckel HB; Franke L; Meineke I; Tzvetkov M; Uebelhack R; Roots I; Brockmöller J
    Pharmacogenet Genomics; 2005 Aug; 15(8):579-87. PubMed ID: 16007002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.
    Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ
    Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.
    Haritos VS; Ghabrial H; Ahokas JT; Ching MS
    Pharmacogenetics; 2000 Oct; 10(7):591-603. PubMed ID: 11037801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
    Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW
    Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
    Pedersen RS; Damkier P; Brosen K
    Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
    Arneth B; Shams M; Hiemke C; Härtter S
    Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
    Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
    Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
    Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
    Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.